Volume 13, Issue 6 pp. 759-762
Original Article

Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease

Charles N. Bernstein MD

Corresponding Author

Charles N. Bernstein MD

University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada

Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

804F-715 McDermot Ave., University of Manitoba, Winnipeg, Manitoba, Canada R3E 3P4Search for more papers by this author
Patricia Rawsthorne RN

Patricia Rawsthorne RN

University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada

Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Search for more papers by this author
James F. Blanchard MD, PhD

James F. Blanchard MD, PhD

University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada

Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

Search for more papers by this author
First published: 17 January 2007
Citations: 5

Abstract

Background: Previous controversy was generated over the hypothesis that a paramyxovirus such as measles or vaccination against such viruses might be causally associated with inflammatory bowel disease (IBD). We aimed to determine if Crohn's disease (CD) or ulcerative colitis (UC) subjects are more likely to be seropositive for measles, mumps, or rubella than controls.

Methods: Using our population-based University of Manitoba IBD Research Registry we recruited CD (n = 235) and UC (n = 137) subjects ages 18–50 years for a study involving detailed questionnaires and venipuncture. We accessed the population-based databases of Manitoba Health (single provincial health insurer) to get age-, gender-, and geography-matched non-IBD controls (n = 310). We used a standard enzyme-linked immunosorbent assay (ELISA) to measure serum antibodies.

Results: Seropositivity for measles and mumps was similar in controls (98.1%, 78.4%, respectively) as in CD (96.2%, 72.3% respectively) and in UC (95.5%, 74.6%, respectively). However, controls were significantly more likely to be seropositive for rubella (98.1%) than were CD cases (91.0%, P < 0.0002) or UC cases (93.3%, P = 0.01). Males accounted for the significantly lower rates of seropositivity to rubella with CD. While we determined that significantly more controls than CD were vaccinated, we cannot be sure if the increased rate of rubella seropositivity in controls is secondary to wildtype or vaccine-associated infection.

Conclusions: These data suggest there is no association of having acquired measles, mumps, or rubella (by natural infection or through vaccination) and CD or UC. If anything, these data may suggest some protective effect of having acquired rubella infection or vaccine against acquiring CD.

(Inflamm Bowel Dis 2007)

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.